Department of Dermatology, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa 259-1193, Japan.
Tokai J Exp Clin Med. 2020 Dec 20;45(4):230-235.
To review patients who were treated at Tokai University Hospital with biologic agents for psoriasis vulgaris and psoriatic arthritis and analyze the biological retention rate, reasons for switching biologics, and investigate possible clinical prognostic factor which may affect whether a patient preferred one biologic to another.
Clinical courses of 63 patients who received biologic agents between Sep of 2010 to June of 2019 were investigated. Biological retention rate of each biologic agents, reasons of switching to another biologic agent, and prognostic factors, if any, between switched and non-switched patients were examined.
The biological retention rate of ustekinumab (UST) was significantly longer than that of infliximab (IFX) or adalimumab (ADA). The major reason of switching was due to secondary loss of efficacy. Patients being treated with UST were more likely to switch to another biologic when they exhibited nail lesions.
These results suggested that biological retention rate of UST was superior than that of IFX or ADA. Furthermore, with patients administered UST, nail symptom suggested possible clinical prognostic factor for switching to other biologic agents.
回顾在东海大学医院接受生物制剂治疗寻常型银屑病和银屑病关节炎的患者，分析生物制剂的保留率、转换生物制剂的原因，并探讨可能影响患者对一种生物制剂优于另一种生物制剂的临床预后因素。
调查了 2010 年 9 月至 2019 年 6 月期间接受生物制剂治疗的 63 例患者的临床病程。检查了每种生物制剂的生物保留率、转换为另一种生物制剂的原因，以及转换和未转换患者之间是否存在预后因素。
乌司奴单抗（UST）的生物保留率明显长于英夫利昔单抗（IFX）或阿达木单抗（ADA）。转换的主要原因是继发疗效丧失。接受 UST 治疗的患者在出现指甲病变时更有可能转换为另一种生物制剂。
这些结果表明，UST 的生物保留率优于 IFX 或 ADA。此外，对于接受 UST 治疗的患者，指甲症状可能是转换为其他生物制剂的临床预后因素。
